Intervention not reported
Function Lequesne algofunctional index 0‐24 (higher scores mean worse) · patients with osteoarthritis
1 finding from 1 review
Intervention not reported
Adverse events Participants (n) reported adverse events · patients with osteoarthritis
The intervention showed no clear difference in adverse events Participants (n) reported adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events Participants (n) withdrew due to adverse effects · patients with osteoarthritis
1 finding from 1 review
Intervention not reported
Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis
1 finding from 1 review
Intervention not reported
Radiographic joint changes · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain (short term) WOMAC scale from 0 to 20 points (higher is worse pain). · patients with osteoarthritis
1 finding from 1 review
Function (short‐term) WOMAC scale from: 0 to 100 (higher is worse function). · patients with osteoarthritis
1 finding from 1 review
Adverse events Participants (n) reported adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
1 finding from 1 review
Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported serious adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
Radiographic joint changes · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Radiographic joint changes · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Pain Global pain VAS 0‐100 (higher scores mean worse) · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
Function WOMAC‐VAS (Function) · patients with treating osteoarthritis
1 finding from 1 review
Intervention not reported
At least 50% of maximum pain relief over 4 to 6 hours · adults with moderate or severe acute postoperative pain
The intervention leads to higher at least 50% of maximum pain relief over 4 to 6 hours (high certainty).
1 finding from 1 review
RR 5.6 [4, 7.8]
Studies not reported
High
Intervention not reported
Participants with at least 1 adverse event · adults with moderate or severe acute postoperative pain
The intervention showed no clear difference in participants with at least 1 adverse event (moderate certainty).
1 finding from 1 review
RR 0.93 [0.74, 1.2]
Studies not reported
Moderate